ARFORMOTEROL TARTRATE

N/A

Manufactured by Alembic Pharmaceuticals Inc.

613 FDA adverse event reports analyzed

Last updated: 2026-04-15

About ARFORMOTEROL TARTRATE

ARFORMOTEROL TARTRATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Alembic Pharmaceuticals Inc.. The most commonly reported adverse reactions for ARFORMOTEROL TARTRATE include DYSPNOEA, FATIGUE, PNEUMONIA, COUGH, CHRONIC OBSTRUCTIVE PULMONARY DISEASE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ARFORMOTEROL TARTRATE.

Top Adverse Reactions

DYSPNOEA39 reports
FATIGUE26 reports
PNEUMONIA19 reports
COUGH15 reports
CHRONIC OBSTRUCTIVE PULMONARY DISEASE14 reports
DRUG INEFFECTIVE14 reports
ASTHENIA11 reports
DIARRHOEA11 reports
PERIPHERAL SWELLING11 reports
MEMORY IMPAIRMENT10 reports
PAIN10 reports
NAUSEA9 reports
OEDEMA PERIPHERAL9 reports
OXYGEN SATURATION DECREASED9 reports
PRODUCT USE ISSUE9 reports
PULMONARY OEDEMA9 reports
ARTHRALGIA8 reports
BRONCHITIS8 reports
DEATH8 reports
DIZZINESS8 reports
GASTROOESOPHAGEAL REFLUX DISEASE8 reports
MALAISE8 reports
NASOPHARYNGITIS8 reports
OFF LABEL USE8 reports
PRODUCT DOSE OMISSION ISSUE8 reports
WEIGHT DECREASED8 reports
CHEST DISCOMFORT7 reports
CONDITION AGGRAVATED7 reports
DECREASED APPETITE7 reports
HEADACHE7 reports
PRODUCT USE IN UNAPPROVED INDICATION7 reports
VOMITING7 reports
BLOOD PRESSURE INCREASED6 reports
COVID 196 reports
DYSPNOEA EXERTIONAL6 reports
FALL6 reports
MYALGIA6 reports
PAIN IN EXTREMITY6 reports
RASH6 reports
ATRIAL FIBRILLATION5 reports
DRUG HYPERSENSITIVITY5 reports
DRY MOUTH5 reports
GAIT DISTURBANCE5 reports
HEART RATE INCREASED5 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION5 reports
INFLUENZA5 reports
MUSCULAR WEAKNESS5 reports
PRODUCTIVE COUGH5 reports
RENAL FAILURE ACUTE5 reports
SINUSITIS5 reports
SLEEP DISORDER5 reports
ASTHMA4 reports
BACK PAIN4 reports
CHEST PAIN4 reports
DRUG INTERACTION4 reports
EPISTAXIS4 reports
HOSPITALISATION4 reports
HYPERLIPIDAEMIA4 reports
HYPOTENSION4 reports
ILLNESS4 reports
INCORRECT DOSE ADMINISTERED4 reports
INFECTION4 reports
INSOMNIA4 reports
INTENTIONAL DOSE OMISSION4 reports
LUNG DISORDER4 reports
NO ADVERSE EVENT4 reports
OROPHARYNGEAL PAIN4 reports
PLEURAL EFFUSION4 reports
ABDOMINAL PAIN3 reports
ABDOMINAL PAIN UPPER3 reports
ALOPECIA3 reports
ANAEMIA3 reports
BLADDER SPASM3 reports
CARDIAC DISORDER3 reports
CARDIAC FAILURE CONGESTIVE3 reports
CONSTIPATION3 reports
DEVICE MALFUNCTION3 reports
DISCOMFORT3 reports
DISEASE RECURRENCE3 reports
DYSPEPSIA3 reports
DYSPHONIA3 reports
EMPHYSEMA3 reports
FEELING ABNORMAL3 reports
FEELING COLD3 reports
FOOD ALLERGY3 reports
GALLBLADDER DISORDER3 reports
GASTROINTESTINAL DISORDER3 reports
GASTROINTESTINAL HAEMORRHAGE3 reports
HYPOXIA3 reports
INSURANCE ISSUE3 reports
LIP SWELLING3 reports
MIDDLE INSOMNIA3 reports
MUSCLE SPASMS3 reports
PARAESTHESIA3 reports
PERICARDIAL EFFUSION3 reports
PRODUCT DOSE OMISSION IN ERROR3 reports
PRURITUS3 reports
RESPIRATORY DISORDER3 reports
SWELLING3 reports
TREMOR3 reports

Report Outcomes

Out of 182 classified reports for ARFORMOTEROL TARTRATE:

Serious 52.2%Non-Serious 47.8%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female93 (56.7%)
Male70 (42.7%)
Unknown1 (0.6%)

Reports by Age

Age 799 reports
Age 638 reports
Age 708 reports
Age 616 reports
Age 816 reports
Age 655 reports
Age 715 reports
Age 624 reports
Age 674 reports
Age 774 reports
Age 563 reports
Age 643 reports
Age 683 reports
Age 743 reports
Age 753 reports
Age 803 reports
Age 863 reports
Age 572 reports
Age 602 reports
Age 662 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with ARFORMOTEROL TARTRATE?

This profile reflects 613 FDA FAERS reports that mention ARFORMOTEROL TARTRATE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for ARFORMOTEROL TARTRATE?

Frequently reported terms in FAERS include DYSPNOEA, FATIGUE, PNEUMONIA, COUGH, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, DRUG INEFFECTIVE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures ARFORMOTEROL TARTRATE?

Labeling and FAERS entries often list Alembic Pharmaceuticals Inc. in connection with ARFORMOTEROL TARTRATE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.